APPENDICURE

For many people diagnosed with appendiceal cancer, one of the first things they learn is that very few treatments were developed specifically for this disease. Most systemic therapies used today were originally designed for colon cancer, even though appendix tumors behave very differently.

But researchers are beginning to understand something important about the biology of appendiceal adenocarcinoma: many of these tumors are driven by KRAS mutations.

A new study presented at the American Association for Cancer Research (AACR) RAS Oncogenesis Conference in March 2026 suggests that drugs designed to target KRAS may be able to slow or even shrink some appendix cancers. Here is the original article released March 5, 2026: KRAS inhibition is an effective therapy for appendiceal adenocarcinoma: Single cell profiling identifies tumor intrinsic and microenvironmental mechanisms unique to appendix cancer

The research is still early, but the findings are notable. In the study, all five patients treated with KRAS inhibitors experienced clinical benefit, including one complete response that is still ongoing.

For a disease that has historically had very limited treatment options, results like these represent an important step toward targeted therapies specifically for appendix cancer.

What This Means For Patients

This new research suggests three important things:

• Many appendix cancers contain KRAS mutations that may be a target for new drugs.
• Early patient results show that KRAS inhibitors can shrink tumors or stop growth in some cases.
• Genomic testing of appendix tumors is increasingly important, because treatment options may depend on the exact KRAS mutation.

These therapies are still being studied, but they represent one of the most promising areas of research in appendix cancer today.

Why KRAS Matters in Appendix Cancer

KRAS is one of the most commonly mutated genes in cancer.

In appendiceal mucinous adenocarcinoma, it appears in nearly 80% of tumors.

KRAS mutations act like a stuck accelerator pedal inside cancer cells. They constantly signal the cell to grow and divide.

For decades, scientists struggled to develop drugs that could block KRAS. It was often called an “undruggable” target.

That has finally started to change.

Over the last few years, researchers have developed a new class of drugs called KRAS inhibitors, and this new study is one of the first to explore whether those drugs might work in appendix cancer.

How KRAS Inhibitors Work

KRAS inhibitors are drugs designed to block the signal that tells cancer cells to grow.

In tumors with KRAS mutations, the KRAS protein stays permanently switched on, continuously sending growth signals inside the cell.

KRAS inhibitors work by turning off that signal, which can:

• slow tumor growth
• stop cancer cells from dividing
• trigger cancer cell death

Because KRAS mutations drive many appendix cancers, blocking this pathway is an area of intense research.

Simple Visuals: How KRAS Drives Appendix Cancer Growth

Normal Cell Signaling

Growth Signal → KRAS → MEK → ERK → Cell Growth

In normal cells, this pathway turns on and off only when needed.

KRAS-Mutated Cancer

Growth Signal → KRAS mutation (stuck ON) → MEK → ERK → Continuous tumor growth

The KRAS mutation acts like a stuck accelerator pedal, continuously telling cancer cells to grow.

Where KRAS Inhibitor Drugs Work

Growth Signal → KRAS mutation → KRAS inhibitor blocks signal → MEK/ERK pathway shut down → Tumor growth slows

KRAS inhibitors aim to turn off the signal that drives tumor growth.

What the Researchers Did

The investigators studied KRAS inhibitors in three ways:

1. Five real appendix cancer patients were treated with KRAS-targeting drugs.
2. Patient-derived tumor models were created in the laboratory.
3. Mouse models implanted with appendix tumors were treated with the same drugs.

The goal was to determine whether blocking KRAS could slow or stop tumor growth.

What Happened in the Patients

All five patients in the study experienced clinical benefit.

The responses included:

• 1 complete response (tumor disappeared)
• 2 partial responses (tumors shrank)
• 2 cases of stable disease

One particularly striking case involved a patient with a KRAS G12D mutation.

That patient received a drug called MRTX1133, a KRAS G12D inhibitor, and achieved a complete response that is still ongoing.

Another patient with advanced disease received a pan-KRAS inhibitor (RMC-6236) as their seventh line of therapy.

Within two months:

• their tumor marker CA19-9 dropped by 66%
• imaging showed a partial response

What the Lab Experiments Showed

In addition to the patient results, the researchers tested these drugs in lab models.

They used:

• Organoids, miniature tumors grown from patient tissue
• PDX mouse models, where human appendix tumors are implanted into mice

The results were notable.

When KRAS inhibitors were used:

• tumor growth slowed dramatically
• cancer cells stopped dividing
• many tumor cells died

In one mouse experiment, all untreated mice died within 60 days, while all mice treated with the KRAS inhibitor were still alive.

Another Interesting Discovery: The Immune System

The researchers also noticed something unexpected.

KRAS inhibition appeared to activate interferon pathways, which are signals associated with the immune system attacking tumors.

This suggests that KRAS inhibitors might not only block tumor growth directly, but could also stimulate immune activity against the cancer.

If confirmed in future studies, it could open the door to combining KRAS inhibitors with immunotherapy.

Which KRAS Mutations are Most Common in Appendix Cancer

KRAS mutations are extremely common in appendiceal adenocarcinoma, particularly in mucinous tumors.

Research suggests that up to 80% of these cancers contain a KRAS mutation.

Some common mutations include:

KRAS G12D
Common in appendix cancer. In the study, tumors with this mutation responded very well to MRTX1133.

KRAS G12V
Often seen in appendix cancer and may respond better to pan-KRAS inhibitors.

KRAS G12C
Less common but important because FDA-approved drugs exist for this mutation in lung cancer.

Because different drugs target different mutations, knowing the exact mutation matters.

Visual Guide: KRAS Mutations and Targeted Drugs

KRAS Mutation	Potential Targeted Therapy
G12D	MRTX1133
G12V	Pan-KRAS inhibitors (RMC-6236)
G12C	Sotorasib, Adagrasib
Other KRAS mutations	Pan-KRAS inhibitors (clinical trials)

Why KRAS and GNAS Mutations Often Occur Together

In mucinous appendiceal cancers, KRAS mutations often occur alongside mutations in another gene called GNAS.

KRAS mutations drive tumor growth, while GNAS mutations appear to influence mucin production, the jelly-like material seen in many appendix tumors and pseudomyxoma peritonei.

In the new research, some patients who benefited from KRAS inhibitors had tumors containing both KRAS and GNAS mutations.

This suggests that KRAS signaling plays a central role in the biology of mucinous appendix cancers.

KRAS Drugs Currently in Clinical Trials

Several KRAS-targeting drugs are now being studied.

MRTX1133
Targets KRAS G12D, a common mutation in appendix cancer.

RMC-6236
A pan-KRAS inhibitor designed to target multiple KRAS mutations.

G12C inhibitors

• Sotorasib
• Adagrasib

Already approved for lung cancer.

Should Appendix Cancer Patients Consider KRAS Inhibitor Trials

KRAS-targeted therapies are not yet standard treatment for appendiceal adenocarcinoma.

However, clinical trials are exploring these drugs across many KRAS-mutated cancers. There are several people in the Appendicure Community who are already participating in these trials.

Patients may want to discuss clinical trials with their oncology team, particularly if their tumor contains a KRAS mutation.

Clinical trials are how new treatments are developed, and for rare cancers like appendix cancer, they are often an important pathway to promising therapies.

What Researchers are Learning About Drug Resistance

The researchers also studied how tumors might eventually adapt to KRAS inhibitors.

They observed increased activity in two pathways:

EMT (Epithelial–Mesenchymal Transition)
A process that can make cancer cells more invasive and resistant to therapy.

TGF-β signaling
A pathway linked to inflammation, tumor progression, and treatment resistance.

Understanding these resistance mechanisms may help researchers design future combination therapies, such as pairing KRAS inhibitors with other targeted drugs or immunotherapy.

The Bottom Line

This research is still early and involves a small number of patients, but the results are encouraging.

The study provides early evidence that KRAS inhibitors may be an effective therapy for appendiceal adenocarcinoma, particularly in tumors with specific KRAS mutations.

If confirmed in larger clinical trials, KRAS inhibitors could become one of the first targeted systemic treatments specifically for appendix cancer.

For patients and caregivers, this research highlights the growing importance of tumor genomic testing and precision medicine.